513 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
GSK GlaxoSmithKline PLC $39.21 $97.25B N/A
Article Searches
Gilead (GILD) Teams Up With Nurix for Cancer and Other Drugs http://www.zacks.com/stock/news/432004/gilead-gild-teams-up-with-nurix-for-cancer-and-other-drugs?cid=CS-ZC-FT-432004 Jun 20, 2019 - Gilead (GILD) collaborates with Nurix Therapeutics to leverage the proprietary drug discovery platform of the latter to identify novel agents that induce degradation of specified drug targets.
Sanofi Partners Google to Build Healthcare Innovation Lab http://www.zacks.com/stock/news/431152/sanofi-partners-google-to-build-healthcare-innovation-lab?cid=CS-ZC-FT-431152 Jun 18, 2019 - Sanofi (SNY) signs a partnership pact with Google to develop a new virtual healthcare innovation lab for modernizing future medicines and healthcare services with sophisticated data technologies.
AstraZeneca/Merck's Lynparza Wins EU Nod for First-Line Use http://www.zacks.com/stock/news/431009/astrazeneca-mercks-lynparza-wins-eu-nod-for-first-line-use?cid=CS-ZC-FT-431009 Jun 18, 2019 - AstraZeneca (AZN) and Merck's PARP inhibitor, Lynparza, gets approval in EU as a front-line therapy for BRCA-mutated advanced ovarian cancer.
Glaxo's Nucala Gets CHMP Nod for 2 Self-Administered Options http://www.zacks.com/stock/news/424909/glaxos-nucala-gets-chmp-nod-for-2-self-administered-options?cid=CS-ZC-FT-424909 Jun 05, 2019 - GlaxoSmithKline (GSK) announces that the EMA???s Committee for Medicinal Products for Human Use has issued a positive opinion for two self-administered options of its asthma drug, Nucala.
Emergent (EBS) Wins HHS Contract to Supply VIGIV Product http://www.zacks.com/stock/news/424736/emergent-ebs-wins-hhs-contract-to-supply-vigiv-product?cid=CS-ZC-FT-424736 Jun 04, 2019 - Shares of Emergent (EBS) rise after the company gets a 10-year HHS contract valued at roughly $535 million to dispense VIGIV product to the U.S. government for supporting its smallpox awareness drive.
Thermo Fisher Acquires GlaxoSmithKline's Drug Production Site http://www.zacks.com/stock/news/415702/thermo-fisher-acquires-glaxosmithklines-drug-production-site?cid=CS-ZC-FT-415702 May 17, 2019 - The latest acquisition aligns with Thermo Fisher's (TMO) strategy of enhancing capabilities of its Pharma Services through the right balance of capital investment, and merger and acquisition.
What's in Store for Axsome (AXSM) This Earnings Season? http://www.zacks.com/stock/news/410492/whats-in-store-for-axsome-axsm-this-earnings-season?cid=CS-ZC-FT-410492 May 07, 2019 - On Axsome's (AXSM) first-quarter earnings call, investors will look for its progress with the CNS pipeline candidates and the regulatory updates on the same.
The Zacks Analyst Blog Highlights: Merck, Pfizer, AbbVie, Sanofi and Glaxo http://www.zacks.com/stock/news/409269/the-zacks-analyst-blog-highlights-merck-pfizer-abbvie-sanofi-and-glaxo?cid=CS-ZC-FT-409269 May 06, 2019 - The Zacks Analyst Blog Highlights: Merck, Pfizer, AbbVie, Sanofi and Glaxo
Pharma Stock Roundup: MRK, LLY, PFE Report Q1 Earnings, SNY, ABBV Drugs Get EU Nod http://www.zacks.com/stock/news/408311/pharma-stock-roundup-mrk-lly-pfe-report-q1-earnings-sny-abbv-drugs-get-eu-nod?cid=CS-ZC-FT-408311 May 03, 2019 - Merck (MRK), Pfizer (PFE), Lilly (LLY) announce Q1 results. European Commission grants approval to AbbVie's (ABBV) Skyrizi and Sanofi's (SNY) Zynquista.
GlaxoSmithKline plc (GSK) Q1 2019 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2019/05/01/glaxosmithkline-plc-gsk-q1-2019-earnings-call-tran.aspx?source=iedfolrf0000001 May 01, 2019 - GSK earnings call for the period ending March 31, 2019.

Pages: 123456...52

Page 1>